Results Patients treated with sacubitril/valsartan in addition to beta-blocker and
mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were …

Background Little information is available about the tolerability of uptitration to the maximal
dose of sacubitril/valsartan and the predictors and clinical correlates of achieving such a …

Aims The poor control of symptoms in patients with advanced heart failure with reduced
ejection function (HFrEF) can limit the functionality of patients. Sacubitril–valsartan …

Abstract Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first
in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Background. Currently, data on sacubitril/valsartan therapy from the real-world settings are
scarce and the predictors of a good clinical responsiveness to this drug are unknown …

Recent clinical trial data have established the safety and efficacy of sacubitril/valsartan, a
first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in the treatment of heart failure …

Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is the
first medication to demonstrate a mortality benefit in patients with chronic heart failure and …